Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial.

Chad R HeatwoleElizabeth LuebbeSpencer RoseroKaty EichingerWilliam MartensJames HilbertJeanne DekdebrunNuran DilekChristine ZizziNicholas JohnsonAraya PuwanantRabi TawilGiovanni SchifittoChristopher A BeckJ Franklin RichesonWojciech ZarebaCharles ThorntonMichael P McDermottRichard Moxley

Published in: Neurology (2020)

This study provides Class I evidence that for ambulatory patients with DM1, mexiletine does not significantly change 6-minute walk distance at 6 months.

Keyphrases

double blind
clinical trial
placebo controlled
blood pressure
study protocol
early onset
randomized controlled trial
type diabetes
phase ii
metabolic syndrome
adipose tissue
glycemic control
open label
insulin resistance